Loading...
OTC Markets
Totals
Securities
12,215
Dollar Vol
$1.7B
Share Vol
2.1B
Trades
213,529

OTC Markets Group uses cookies and similar technologies to help us understand how you use our websites, as further disclosed in our Privacy Policy. Our Terms of Service contain important information including restrictions on your use of our websites. By clicking “Accept”, or by continuing to use our websites, you consent to the use of cookies and agree to the terms of the OTC Markets Group Privacy Policy and Terms of Service.

FLHLF
Filament Health Corp.

Ordinary Shares

Filament Health Corp.

4475 Wayburne Drive

Unit 210

Burnaby, BC V5G 4X4

Canada

Business Description
Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament engages in natural extraction technology commercialization, utilizing its intellectual property portfolio, in house GMP facility, and Health Canada Dealers License for all natural psychedelics. Filament is headquartered in Vancouver, British Columbia.
Financial Reporting
Reporting Status
International Reporting: Foreign Issuer - Not Listed on Foreign Exchange
Audited Financials
Audited
Fiscal Year End
12/31
Company Officers & Contacts
Benjamin Theodore Lightburn
CEO, Co-Founder

Lisa Frances Ranken
COO

Steven Nguyen
Interim CFO

Ryan Moss
Chief Scientific Officer

Board of Directors
Michael Messinger
Chairman, Independent Director, Audit Committee Member

Konstantin Adamsky
Independent Director, Audit Committee Member

Jonathan William Conlin
Independent Director, Compensation Committee Member, Nominating Committee Member

Benjamin Theodore Lightburn
CEO, Co-Founder

Other Company Insiders

None

Other Company Insiders are all persons or entities beneficially owning 10% or more of any class of the issuer's securities. Together, officers, directors and other company insiders comprise Company Insiders.
Service Providers
Accounting/Auditing Firm
MNP LLP

1500, 640 - 5th Avenue SW

Calgary, AB T2P 3G4

Canada

Securities Counsel
Fasken Martineau DuMoulin LLP - Vancouver, British Columbia (Canada)

550 Burrard Street, Suite 2900

Vancouver, BC V6C 0A3

Canada

Profile Data
SIC - Industry Classification
Not Available
Incorporation Information
BC, CA, 2020
Employees
11 as of 06/30/2023
Shell
No
Products and Services

For pharmaceutical clinical trial candidates, Filament possesses the capabilities to manufacture in-house clinical drug candidates. In addition, Filament’s capabilities allow it to manufacture drug candidates for third parties wishing to pursue their own clinical development program. In these cases, Filament and the third parties will enter into intellectual property licensing agreements whereby Filament will potentially earn commercial milestones and royalty payments based upon future levels of commercialization met by the third party clinical development program. Filament’s first three botanical drug candidates are standardized, purified extracts of psilocybe cubensis fruiting bodies include: - PEX010 Psilocybin - oral delivery (1mg and 25mg) - PEX020 Psilocin - oral delivery (dose withheld) - PEX030 Psilocin - sublingual delivery (dose withheld) PEX010, PEX020 and PEX030 have successfully attained FDA Botanical Drug classification, a unique development pathway in comparison to isolated natural and synthetic compounds. As of March [31], 2022, Filament’s PEX010 drug candidate also obtained approval from Health Canada to be administered in clinical trials. Filament has also developed the following standardized drug candidates which are in preclinical stage: - AEX010 Ayahuasca - oral delivery (dose withheld) - AEX020 Monoamine Oxidase Inhibitor - oral delivery (dose withheld)

Company Facilities

Fully operational mycology lab, production facility and head office located at 4475 Wayburne Drive, Unit 210, Burnaby, British Columbia, V5G 4X4. The Burnaby facility includes cultivation space and laboratory space used for the preparation of genetic material for the cultivation and manufacturing process. The processing space and equipment allows for the drying, extraction, purification and standardization of psychedelic substances. There is also a secure controlled substances environ that is only accessible to authorized individuals. The Burnaby facility measures 3,416 square feet and is a leased facility. Psilo’s GMP manufacturing, Dealer’s License and manufacturing capabilities enable Psilo to supply in-house human clinical trials as well as license technology to drug developers, researchers and other licensed parties.

Company Notes
Formerlly=Filament Ventures Corp. until 06-2021
Expert Market Icon
This market serves broker-dealer pricing and investor best execution needs. Quotations in Expert Market securities are restricted from public viewing.
Expert Market
The Company Profile data was verified by the issuer within the previous 6 months.
The company’s transfer agent has verified its outstanding shares directly to OTC Markets.
The Company’s board of directors includes at least two Independent Directors.
Daily Advancers
Subscribe to Our Newsletter
Stay up to date on the latest company news, industry trends and regulatory changes that affect our markets and learn about members of our community.